161 related articles for article (PubMed ID: 21213036)
1. Does hormone therapy counter the beneficial effects of physical activity on breast cancer risk in postmenopausal women?
Dieli-Conwright CM; Sullivan-Halley J; Patel A; Press M; Malone K; Ursin G; Burkman R; Strom B; Simon M; Weiss L; Marchbanks P; Folger S; Spirtas R; Deapen D; Bernstein L
Cancer Causes Control; 2011 Mar; 22(3):515-22. PubMed ID: 21213036
[TBL] [Abstract][Full Text] [Related]
2. Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort.
Wang SM; Pfeiffer RM; Gierach GL; Falk RT
Breast Cancer Res; 2020 Nov; 22(1):129. PubMed ID: 33239054
[TBL] [Abstract][Full Text] [Related]
3. Menopausal hormone therapy and risk of epithelial ovarian cancer.
Rossing MA; Cushing-Haugen KL; Wicklund KG; Doherty JA; Weiss NS
Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2548-56. PubMed ID: 18086757
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use.
Kerlikowske K; Cook AJ; Buist DS; Cummings SR; Vachon C; Vacek P; Miglioretti DL
J Clin Oncol; 2010 Aug; 28(24):3830-7. PubMed ID: 20644098
[TBL] [Abstract][Full Text] [Related]
5. Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index.
Chlebowski RT; Anderson GL; Aragaki AK; Prentice R
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26546117
[TBL] [Abstract][Full Text] [Related]
6. Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study.
DeBono NL; Robinson WR; Lund JL; Tse CK; Moorman PG; Olshan AF; Troester MA
J Womens Health (Larchmt); 2018 Mar; 27(3):377-386. PubMed ID: 28570827
[TBL] [Abstract][Full Text] [Related]
7. Forty-year trends in menopausal hormone therapy use and breast cancer incidence among postmenopausal black and white women.
Chlebowski RT; Aragaki AK; Anderson GL; Prentice RL
Cancer; 2020 Jul; 126(13):2956-2964. PubMed ID: 32212335
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in hormone metabolism and growth factor genes and mammographic density in Norwegian postmenopausal hormone therapy users and non-users.
Ellingjord-Dale M; Lee E; Couto E; Ozhand A; Qureshi S; Hofvind S; Van Den Berg DJ; Akslen LA; Grotmol T; Ursin G
Breast Cancer Res; 2012 Oct; 14(5):R135. PubMed ID: 23095343
[TBL] [Abstract][Full Text] [Related]
9. Do breast cancer risk factors modify the association between hormone therapy and mammographic breast density? (United States).
Aiello EJ; Buist DS; White E
Cancer Causes Control; 2006 Dec; 17(10):1227-35. PubMed ID: 17111253
[TBL] [Abstract][Full Text] [Related]
10. Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone?
Falk RT; Manson JE; Barnabei VM; Anderson GL; Brinton LA; Rohan TE; Cauley JA; Chen C; Coburn SB; Pfeiffer RM; Reding KW; Sarto GE; Wentzensen N; Chlebowski RT; Xu X; Trabert B
Int J Cancer; 2019 Feb; 144(4):730-740. PubMed ID: 30183089
[TBL] [Abstract][Full Text] [Related]
11. Is breast cancer risk the same for all progestogens?
Stute P
Arch Gynecol Obstet; 2014 Aug; 290(2):207-9. PubMed ID: 24838289
[TBL] [Abstract][Full Text] [Related]
12. Postmenopausal estrogen and progestin use in relation to breast cancer risk.
Newcomb PA; Titus-Ernstoff L; Egan KM; Trentham-Dietz A; Baron JA; Storer BE; Willett WC; Stampfer MJ
Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):593-600. PubMed ID: 12101105
[TBL] [Abstract][Full Text] [Related]
13. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis.
Rovinski D; Ramos RB; Fighera TM; Casanova GK; Spritzer PM
Thromb Res; 2018 Aug; 168():83-95. PubMed ID: 29936403
[TBL] [Abstract][Full Text] [Related]
14. Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States).
Li CI; Malone KE; Daling JR
Cancer Causes Control; 2006 Jun; 17(5):695-703. PubMed ID: 16633917
[TBL] [Abstract][Full Text] [Related]
15. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.
Eisen A; Lubinski J; Gronwald J; Moller P; Lynch HT; Klijn J; Kim-Sing C; Neuhausen SL; Gilbert L; Ghadirian P; Manoukian S; Rennert G; Friedman E; Isaacs C; Rosen E; Rosen B; Daly M; Sun P; Narod SA;
J Natl Cancer Inst; 2008 Oct; 100(19):1361-7. PubMed ID: 18812548
[TBL] [Abstract][Full Text] [Related]
16. Exogenous Hormone Use and Endometrial Cancer in U.S. Black Women.
Sponholtz TR; Palmer JR; Rosenberg LA; Hatch EE; Adams-Campbell LL; Wise LA
Cancer Epidemiol Biomarkers Prev; 2018 May; 27(5):558-565. PubMed ID: 29475971
[No Abstract] [Full Text] [Related]
17. Different menopausal hormone regimens and risk of breast cancer.
Brusselaers N; Tamimi RM; Konings P; Rosner B; Adami HO; Lagergren J
Ann Oncol; 2018 Aug; 29(8):1771-1776. PubMed ID: 29917061
[TBL] [Abstract][Full Text] [Related]
18. Body size in early life and breast cancer risk in African American and European American women.
Bandera EV; Chandran U; Zirpoli G; Ciupak G; Bovbjerg DH; Jandorf L; Pawlish K; Freudenheim JL; Ambrosone CB
Cancer Causes Control; 2013 Dec; 24(12):2231-43. PubMed ID: 24113797
[TBL] [Abstract][Full Text] [Related]
19. Screening mammography use among current, former, and never hormone therapy users may not explain recent declines in breast cancer incidence.
Buist DS; Walker R; Bowles EJ; Carney PA; Taplin SH; Onega T; Kerlikowske K; Clinton W; Miglioretti DL
Cancer Epidemiol Biomarkers Prev; 2012 May; 21(5):720-7. PubMed ID: 22301831
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer susceptibility associated with rs1219648 (fibroblast growth factor receptor 2) and postmenopausal hormone therapy use in a population-based United States study.
Andersen SW; Trentham-Dietz A; Figueroa JD; Titus LJ; Cai Q; Long J; Hampton JM; Egan KM; Newcomb PA
Menopause; 2013 Mar; 20(3):354-8. PubMed ID: 23435034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
